Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis.

[1]  R. Duarte,et al.  Why does it take so long? The reasons behind tuberculosis treatment delay in Portugal. , 2019, Pulmonology.

[2]  M. Chang,et al.  Predictors for false-negative QuantiFERON-TB Gold assay results in patients with extrapulmonary tuberculosis , 2018, BMC Infectious Diseases.

[3]  D. Koelle,et al.  Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection , 2018, Open forum infectious diseases.

[4]  Yan Li,et al.  The risk factor of false‐negative and false‐positive for T‐SPOT.TB in active tuberculosis , 2018, Journal of clinical laboratory analysis.

[5]  H. El‐Serag,et al.  Factors That Contribute to Indeterminate Results From the QuantiFERON‐TB Gold In‐Tube Test in Patients With Inflammatory Bowel Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  H. Sugiyama,et al.  Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  Jie Yan,et al.  Usefulness of interferon-γ release assay for the diagnosis of sputum smear-negative pulmonary and extra-pulmonary TB in Zhejiang Province, China , 2017, Infectious Diseases of Poverty.

[8]  A. Matteelli,et al.  Tuberculosis elimination and the challenge of latent tuberculosis. , 2017, Presse medicale.

[9]  M. Grobusch,et al.  Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  H. So,et al.  Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents. , 2017, Hong Kong medical journal = Xianggang yi xue za zhi.

[11]  J. Ernst,et al.  The Challenge of Latent TB Infection. , 2016, JAMA.

[12]  Hai-tao Yang,et al.  Interferon-Gamma Release Assays for the Diagnosis of Tuberculosis: A Systematic Review and Meta-analysis , 2016, Lung.

[13]  C. Suh,et al.  Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA , 2016, Lupus.

[14]  F. Mechaï,et al.  Utility of QuantiFERON-TB Gold In-Tube assay in adult, pulmonary and extrapulmonary, active tuberculosis diagnosis. , 2016, International Journal of Infectious Diseases.

[15]  Ross J. Harris,et al.  Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries , 2015, European Respiratory Journal.

[16]  Y. Ryu,et al.  Factors that Predict Negative Results of QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis: A Multicenter Retrospective Cohort Study , 2015, PloS one.

[17]  P. Hopewell,et al.  Reduced sensitivity of the QuantiFERON(®) test in diabetic patients with smear-negative tuberculosis. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  R. Duarte,et al.  Who are the patients with extrapulmonary tuberculosis? , 2015, Revista portuguesa de pneumologia.

[19]  K. Dheda,et al.  False-negative interferon-γ release assay results in active tuberculosis: a TBNET study , 2014, European Respiratory Journal.

[20]  B. Marshall,et al.  Extremes of Age Are Associated with Indeterminate QuantiFERON-TB Gold Assay Results , 2014, Journal of Clinical Microbiology.

[21]  E. Hershfield,et al.  Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection , 2013, Pediatric Clinical Practice Guidelines & Policies.

[22]  E. Chiappini,et al.  Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a 2013 update , 2014, BMC Infectious Diseases.

[23]  M. Pai,et al.  Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection , 2014, Clinical Microbiology Reviews.

[24]  W. M. Mac Kenzie,et al.  Association between tuberculin skin test result and clinical presentation of tuberculosis disease , 2013, BMC Infectious Diseases.

[25]  S. Bae,et al.  Interferon‐gamma release assays versus tuberculin skin testing in patients with rheumatoid arthritis , 2013, International journal of rheumatic diseases.

[26]  M. Hoelscher,et al.  QuantiFERON®-TB Gold In-Tube Performance for Diagnosing Active Tuberculosis in Children and Adults in a High Burden Setting , 2012, PloS one.

[27]  Suhyun Kim,et al.  Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis , 2012, Tuberculosis and respiratory diseases.

[28]  Claudia Giehl,et al.  Interferon-γ release assays for the diagnosis of active tuberculosis: A systematic review and meta-analysis (European Respiratory Journal (2011) 37, (100-111)) , 2012 .

[29]  K. Steingart,et al.  Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. , 2011, The Journal of infectious diseases.

[30]  S. Tsikrika,et al.  Comparison of Two Gamma Interferon Release Assays and Tuberculin Skin Testing for Tuberculosis Screening in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor Therapy , 2011, Clinical and Vaccine Immunology.

[31]  K Dheda,et al.  Interferon-&ggr; release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis , 2010, European Respiratory Journal.

[32]  R. Diel,et al.  Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. , 2010, Chest.

[33]  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) , 2009, Annals of the rheumatic diseases.

[34]  Y. Obase,et al.  Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice , 2009, European Respiratory Journal.

[35]  L. Fabbri,et al.  Performance of Commercial Blood Tests for the Diagnosis of Latent Tuberculosis Infection in Children and Adolescents , 2009, Pediatrics.

[36]  Madhukar Pai,et al.  Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update , 2008, Annals of Internal Medicine.

[37]  T. Klein,et al.  Addictive drugs and their relationship with infectious diseases. , 2006, FEMS immunology and medical microbiology.

[38]  B. Samten,et al.  Contribution of CD8+ T Cells to Gamma Interferon Production in Human Tuberculosis , 2001, Infection and Immunity.

[39]  P. Barnes,et al.  Clinical Correlates of Interferon γ Production in Patients with Tuberculosis , 1997 .

[40]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[41]  C. C. Heuvelingsa,et al.  Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations , 2017 .

[42]  A. Houston,et al.  Extrapulmonary tuberculosis , 2013 .

[43]  A. Benedetti,et al.  Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis [Review article]. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[44]  P. Dewan,et al.  Low Sensitivity of a Whole-Blood Interferon-γ Release Assay for Detection of Active Tuberculosis , 2007 .

[45]  G. Vanham,et al.  Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.